BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Duchenne muscular dystrophy

Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy

July 27, 2017 By Cade Hildreth (CEO) Leave a Comment

Capricor CAP-1002

Capricor developing IV treatment for DuchenneLOS ANGELES, July 27, 2017 — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it has received official minutes of the meeting held recently between the U.S. Food and Drug Administration (FDA) and Capricor to discuss the development of intravenous CAP-1002 (allogeneic cardiosphere-derived cells) for the treatment of Duchenne muscular dystrophy (DMD).

[Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: CAP-1002, Capricor, CDCs, Duchenne muscular dystrophy, fda

How are Stem Cells Making an Impact on Treatment for Duchenne Muscular Dystrophy?

February 6, 2016 By Cade Hildreth (CEO) Leave a Comment

How are Stem Cells Making an Impact on Treatment for Duchenne Muscular Dystrophy? - Human Heart Anatomy

Hear Dr. Eduardo Marbán, Director of the Cedars-Sinai Heart Institute, speak about how breakthroughs in the application of stem cells for diseases related to the heart have led to new possibilities in treating Duchenne muscular dystrophy.  See the video below, followed by some key points to take away from this post.

Key Points Include:

  • After discovering the heart possesses its own supply of stem cells, Dr. Marbán and his team worked to isolate these stem cells and grow them.  When the stem cells were reintroduced to patients who had suffered heart attacks, the cells reformed heart tissue and reduced scarring!
  • With help through a grant from Coalition Duchenne, a non-profit dedicated to raising awareness of and funding for Duchenne muscular dystrophy (DMD), Dr. Marbán and his team have begun to apply their findings for treatment of DMD
  • DMD is a form of muscular dystrophy caused by a lack of production of dystrophin, a protein that connects muscle fibers together.  It is a rare genetic disorder linked with the X chromosome, and therefore primarily affects boys
  • Trials in which stem cells were injected in the hearts of mice with a DMD-like phenotype showed that not only did their heart function improve and scar tissue shrink, but the mice showed enhanced motor function
  • The success of the mice trials gives major promise for human testing.  If scar tissue is shown to reduce over a longterm period following treatment, it would be a major victory for patients tackling DMD!

About Us

BioInformant.com is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

Filed Under: Stem Cells Tagged With: Cedars-Sinai Heart Institute, Coalition Duchenne, Duchenne muscular dystrophy, Eduardo Marban, stem cells

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.